HLA-A*0201 & B2M & NY-ESO-1 (SLLMWITQV)

HLA-A*0201 & B2M & NY-ESO-1 (SLLMWITQV) Produktliste

Attribut
Protein (5)
Produktbibliothek
Online (5)
Spezies
Human (5)
Etikett
His Tag (2)Flag Tag & Avi Tag (2)Flag Tag (1)
Marker
PE Labeled (1)APC Labeled (1)Biotin-labeled (1)Unconjugated (2)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Vorbestellen/Bestellen
HOT HL1-HA2H8	Human	HEK293	APC-Labeled Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein	In den Warenkorb legen
HL1-H52C6	Human	HEK293	Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein (MALS & SPR verified)	In den Warenkorb legen
HL1-H52T3	Human	HEK293	Unconjugated Human HLA-A*02:01 & B2M & NY-ESO-1 (SLLMWITQV) Complex Protein (Monomer, MALS verified)	In den Warenkorb legen
HL1-H82T3	Human	HEK293	Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Complex Protein (Monomer, MALS verified)	In den Warenkorb legen
HL1-HP2E6	Human	HEK293	PE-Labeled Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein	In den Warenkorb legen

Gesamtmenge5

HLA-A*0201 & B2M & NY-ESO-1 (SLLMWITQV) Molekülhintergrund

NY-ESO-1, which is also well-known as New York esophageal squamous cell carcinoma 1, is an efficient target for cancer immunotherapy. This antigen is a member of cancer-testis antigens (CTAs) and is highly expressed in various cancers, including melanoma, ovarian, cervical cancer, etc. Adoptive T cell therapy with HLA-A2 restricted NY-ESO-1 transduced CD8+ T cells has improved the clinical response rates and overall survival of treatment-refractory melanoma patients. The Human HLA-A*0201 NY-ESO-1 complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M and SLLMWITQV peptide of the NY-ESO-1.

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
ATL-1102	ATL-1102; ATL/TV-1102; ISIS-107248; TV-1102	Phase 2 Clinical	Ionis Pharmaceuticals Inc	Multiple Sclerosis; Muscular Dystrophy, Duchenne	Details
BIIB-107(Biogen)	BIIB-107	Phase 1 Clinical	Biogen Inc	Multiple Sclerosis	Details
ELND-004	ELND-004	Phase 1 Clinical	Perrigo Company Plc	Autoimmune Diseases	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Natalizumab biosimilar(Polpharma Biologics)	PB-006; DST-356A1	Approved	Polpharma Biologics Sa	Tyruko	United States	Crohn Disease; Multiple Sclerosis	Sandoz Inc	2023-08-24	Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Crohn Disease	Details